

**Miguel Abboud**

American University of Beirut, LEBANON

**Françoise Bernaudin**

Centre Hospitalier Intercommunal Créteil, FRANCE

**Enric Carreras**Fundació Josep Carreras Contra la Leucèmia  
Barcelona, SPAIN**Fabio Ciceri**

San Raffaele Scientific Institute Milan, ITALY

**Selim Corbacioglu**

University Children's Hospital Regensburg, GERMANY

**Jean-Hugues Dalle**

Hospital Robert Debre Paris, FRANCE

**Roswitha Dickerhoff**Klinik für Kinder-Onkologie,-Hämatologie und Klin.  
Immunologie Düsseldorf, GERMANY**Josu de la Fuente**

St. Mary's Hospital London, UK

**Lawrence Faulkner**Sankalp-People Tree Hospitals, Bangalore, India  
Cure2Children Foundation, ITALY**Eliane Gluckman**Eurocord University Paris- Diderot and Centre  
Scientifique de Monaco, MONACO**Tayfun Güngör**

Kinderspital Zürich, SWITZERLAND

**Rupert Handgretinger**

Children's Hospital, University of Tübingen, GERMANY

**Anette Hoferer**

Robert-Bosch-Krankenhaus Stuttgart, GERMANY

**Andrea Jarisch**

Children's Hospital, University of Frankfurt, GERMANY

**Julie Makani**

Muhimbili University, TANZANIA

**Stephan Mielke**

Karolinska Institute Stockholm, SWEDEN

**Dietger Niederwieser**

University Hospital Leipzig, GERMANY

**Jean-Antoine Ribeil**Biotherapy Department, Necker Children's Hospital  
Paris, FRANCE**David Williams**

Boston Children's Hospital, Boston, USA

**Volker Witt**

St Anna's Kinderspital Vienna, AUSTRIA

**Scientific Leadership**Prof. Dr. Selim Corbacioglu  
Professor of Pediatrics  
KUNO Children's Hospital  
University Hospital Regensburg**Congress Venue**Auktionshaus Keup  
Haidplatz 7, 93047 Regensburg, Germany**Congress Management**Congress Division UK3, Britta Haseneder  
University Hospital Regensburg  
93042 Regensburg, Germany  
Phone: +49 941 944-4230  
Fax: +49 941 944-4233  
E-mail: kongresse@ukr.de**Registration**Online registration under:  
[www.congress-registration.ukr.de](http://www.congress-registration.ukr.de)**Congress Fee**

Both days	100 €
Conference Dinner	50 €

**Registration conditions**

After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. Delayed cancellations or nonattendance will not be reimbursed.


CME credits can be obtained.

**Sponsors**

Gilead Sciences GmbH	2.000 €
Medac	4.500 €
Miltenyi Biotec GmbH	4.000 €
Neovii	2.500 €
SanofiGenzyme	600 €

We thank all sponsors for their support of this conference.

Sponsoring performance for booth fee and advertising purposes.


**Department of Pediatric Hematology, Oncology  
and Stem Cell Transplantation**
**4. INTERNATIONAL MEETING ON SICKLE CELL  
DISEASE - CURE OR PROCRASTINATION?**

Auktionshaus Keup, Haidplatz 7, 93047 Regensburg, Germany

29 - 30 June 2017

**Dear colleagues and friends,**

I would like to invite you to the 4th international meeting on sickle cell disease.

Sickle cell disease is one of the most prevalent, debilitating, enigmatic diseases worldwide. In developing countries, the mortality in infancy and childhood remains persistently high. In developed countries, despite optimal medical care, a prolonged average overall survival can be achieved but the quality of life for most patients remains dismal. Sickle cell disease is, however, curable.

Stem cell transplantation is currently the only curative option, but is offered to only a few patients. The reasons are lack of knowledge and donor availability according to established criteria. Haploidentical stem cell transplantation has advanced enormously within the last decade, making a donor available for almost every patient. Safety and wide applicability has rendered this procedure increasingly a standard of care for many diseases. Its broader application in sickle cell disease must therefore be considered for obvious reasons.

Gene therapy, on the other hand is an intriguing option for a monogenetic disease but has not yet reached sufficient safety and stability to hit 'mainstream'. Additionally, many novel agents are in development to manipulate hemoglobin expression and polymerization and promise a simple cure. The long-term efficacy of chronic medication on systemic organ damage inflicted by sickle cell disease is unsure.

In the end the question is cure or procrastination. Both options bare risks and promises.

This meeting will provide us an overview of a variety of sickle related topics, including current treatment strategies and an outlook on future options to tackle this highly debilitating disease.

It is my pleasure to welcome you to Regensburg, a medieval city of a notable history, spanning two millennia, from ancient Roman history to today, and experience Bavarian hospitality in a UNESCO world heritage site.

Selim Corbacioglu  
Professor of Pediatrics  
KUNO Children's Hospital, University Hospital Regensburg

**Thursday, 29.06.2017**

11:30	<b>Lunch</b>
12:40	<b>Welcome Reception</b> Selim Corbacioglu, Regensburg & Dietger Niederwieser, Leipzig on behalf of the WBMT
	<b>Session 1</b>
13:00	<b>What is the optimal medical care for patients with SCD? Do your ,homework' prior to transplantation.</b> Roswitha Dickerhoff, Düsseldorf
13:20	<b>Impact of iron chelation therapy in stem cell transplantation.</b> Andrea Jarisch, Frankfurt
13:40	<b>Transition and adult SCD patients: A different challenge.</b> Anette Hoferer, Stuttgart
14:00	<b>Non-transplant alternatives: new and developing therapies for sickle cell disease.</b> Miguel Abboud, Beirut
14:20	<b>What's new in the detection and the management of cerebral vasculopathy in sickle cell anemia?</b> Francoise Bernaudin, Créteil
14:40	<b>How to avoid alloimmunization in SCD?</b> Volker Witt, Vienna
15:00	<b>Sickle cell disease: a risk factor for post-transplant endothelial complications?</b> Enric Carreras, Barcelona
15:20	<b>Coffee Break</b>
	<b>Session 2</b>
15:50	<b>Haploidentical stem cell transplantation – State of the Art.</b> Rupert Handgretinger, Tübingen
16:10	<b>Overview of the current indication and results of hematopoietic stem cell transplantation in patients with with sickle cell disease.</b> Eliane Gluckman, Paris
16:30	<b>What are the options for bone marrow transplant for sickle cell disease in Africa: Experience from Tanzania?</b> Julie Makani, Tanzania
16:50	<b>BMT for hemoglobinopathies in lower income settings: opportunities and challenges.</b> Lawrence Faulkner, Bangalore
17:10	<b>Haploidentical BMT to expand donor availability: The post-transplantation cyclophosphamide experience.</b> Josu de la Fuente, London

17:30	<b>Haploidentical SCT in SCD: the CD3/CD19 experience.</b> Selim Corbacioglu, Regensburg
17:50	<b>How to bridge the gap in haploidentical SCT? Means of accelerated immune reconstitution.</b> Stephan Mielke, Stockholm
18:10	<b>Fertility preservation during Stem Cell Transplantation in Semi-elective/non-malignant Diseases for all ages? State of the art and beyond.</b> Jean-Hugues Dalle, Paris
18:30	<b>Hepatic VOD despite targeted PK-based Busulfan administration in high-risk patients.</b> Tayfun Güngör, Zurich
20:00	<b>Conference Dinner</b>

**Friday, 30.06.2017**

	<b>Session 3</b>
09:00	<b>Clinical outcomes of gene therapy with BB305 lentiviral vector for SCD and <math>\beta</math>-Thalassemia.</b> Jean-Antoine Ribeil, Paris
09:20	<b>Targeting BCL11A using shRNA embedded miRNAs (shRNA<sup>miRNAs</sup>) in Lentiviral vectors for treatment of <math>\beta</math>-hemoglobinopathies.</b> David Williams, Boston
09:40	<b>Autologous HSC-based gene therapy in beta-thalassemia and SCD: Current status and perspectives.</b> Fabio Ciceri, Milan
10:10	<b>Coffee Break</b>
10:30	<b>Discussion and Conclusions</b>
12:00	<ul style="list-style-type: none"> <li>• What is the role of modern conventional treatment options?</li> <li>• Is SCT the best curative option for SCD patients?</li> <li>• What can be optimized prior to HSCT to reduce TRM?</li> <li>• How much fertility preservation?</li> <li>• When is the best time point for HSCT in SCD patients? Should the current indications for HSCT in SCD patients be maintained?</li> <li>• Is the current donor selection process still state of the art?</li> <li>• What should be considered for conditioning?</li> <li>• How to manage post-SCT immune suppression for SCD patients?</li> <li>• Gene therapy: What to expect when we are expecting?</li> <li>• Et al.</li> </ul>
12:00	<b>Lunch</b>